Petrelintide
A long-acting amylin analog with published phase 1 safety, pharmacokinetic, and weight data.
Evidence-led profile
Research snapshot
- Evidence stage
- Investigational; phase 1 published human research
- References
- 1 linked sources
- Research coverage
- 1 area
- Editorial review
- Sep 30, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
The published phase 1 report describes two randomized, controlled studies, with up to 8.6% weight reduction after 16 weeks and an approximately 10-day half-life. These were early-phase studies, and the maximum reported result should not be read as the average effect of all studied groups. Later phase 2 topline statements are sponsor-reported until full results are published.
Research
Phase 1 human studies
Two randomized phase 1 studies reported up to 8.6% weight reduction after 16 weeks and an approximately 10-day half-life. The result is early and not a direct comparison with other agents. Original report.
Safety and Limitations
Phase 1 results cannot resolve rare or long-term adverse effects or establish superiority in tolerability over another treatment. Petrelintide had no FDA-approved U.S. product identified at this review.
Mechanism of Action
Long-acting amylin analog investigated for effects on appetite and weight regulation.
Pharmacokinetic Profile
- Half-life
- Approximately 10 days in reported phase 1 studies; formulation and study conditions matter
From the published phase 1 report, not an approved product label.
References (1)
Continue researching Petrelintide
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.